ArticleRespiratory medicine case reports2022
Photodynamic therapy for treatment of recurrent adenocarcinoma of the lung with tracheal oligometastasis.
Article in Respiratory medicine case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination of Photodynamic and Bronchoscopic Intervention With Radiation Therapy in Treating Pulmonary Pleomorphic Sarcoma: A Case Report.The clinical respiratory journal · 2025Article
- Photodynamic Therapy: From the Basics to the Current Progress ofMolecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tracheal neoplasms account for less than 0.1% of all malignancies. The majority of tracheal malignancies are secondary neoplasms from direct tracheal invasion from adjacent structures and less commonly from hematogenous or lymphatic spread from distal malignancies. Evidence-based guidelines for management are lacking. Less invasive bronchoscopic ablation modalities are an option for non-operable patients. We report a case of endotracheal oligometastatic adenocarcinoma successfully treated with photodynamic therapy. Case: A 59-year-old man with past medical history of stage 1 right upper and left upper lobe neoplasm treated with right lobectomy 2 years ago and wedge resection of the lingula ten months ago presented with cough and hemoptysis. Flexible bronchoscopy revealed a 10 mm endoluminal exophytic lesion of the mid-trachea confirmed as lung adenocarcinoma on biopsy. Considering the lack of extra-cartilaginous spread and the small size, a multidisciplinary team recommended local treatment using photodynamic therapy. Surveillance biopsies out to 2 years confirmed lack of disease recurrence. The patient did not experience any adverse effects. Conclusion: PDT as first line therapy for a 10 mm oligometastatic endotracheal adenocarcinoma from recurrent pulmonary malignancy with no extra-cartilaginous spread is an effective modality that is well tolerated and produces a durable response, which in our patient led to complete response without recurrence at 24 months and with no adverse effects or complications. Determining depth of tumor penetration is paramount if the treatment is with curative intent. PDT should be considered as part of a multidisciplinary approach for endotracheal malignant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.